New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSyn-Coll vs Prostamax

Syn-Coll vs Prostamax

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Syn-Coll
Anti-Aging & Longevity
Prostamax
Summary
Syn-Coll is a palmitoylated tripeptide (Palmitoyl Tripeptide-5) that mimics thrombospondin-1 to activate TGF-beta, the primary growth factor driving collagen synthesis in the dermis. It is one of the most mechanistically direct collagen-stimulating peptides in cosmetic formulations.
Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
Half-Life
Extended (lipid depot in stratum corneum)
Short (minutes); sustained gene-regulatory effects
Admin Route
Topical
SubQ, Oral
Research
Typical Dose
0.005-0.05% in formulation
10 mg per day
Frequency
Once or twice daily
Daily for 10–30 days
Key Benefits
  • Directly activates TGF-beta for potent collagen synthesis stimulation
  • Increases dermal thickness and firmness
  • Reduces depth of wrinkles and fine lines
  • Improves skin elasticity
  • Clinically validated in collagen induction studies
  • Complementary to retinoids or vitamin C
  • Supports normalization of prostate tissue architecture
  • May reduce prostate enlargement associated with BPH
  • Anti-inflammatory effects on prostatic tissue
  • Reduces prostate cell apoptosis from oxidative stress
  • Potential support in chronic prostatitis
  • Anti-aging effects on prostate glandular tissue
  • Complementary to conventional BPH therapies
Side Effects
  • Generally well-tolerated
  • Rare mild irritation at high concentrations
  • Possible sensitivity in individuals with inflammatory skin conditions
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse urological events reported at standard doses
Stacks With